

Jürgen Gränberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3560521/publications.pdf>

Version: 2024-02-01

38
papers

2,311
citations

218677

26
h-index

330143

37
g-index

38
all docs

38
docs citations

38
times ranked

2274
citing authors

#	ARTICLE	IF	CITATIONS
1	L1 Cell Adhesion Molecule Confers Radioresistance to Ovarian Cancer and Defines a New Cancer Stem Cell Population. <i>Cancers</i> , 2020, 12, 217.	3.7	23
2	Novel Therapeutic Strategies for Ovarian Cancer Stem Cells. <i>Frontiers in Oncology</i> , 2020, 10, 319.	2.8	44
3	Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma. <i>BMC Cancer</i> , 2018, 18, 922.	2.6	10
4	Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model. <i>EJNMMI Research</i> , 2014, 4, 54.	2.5	13
5	Future prospects for SPECT imaging using the radiolanthanide terbium-155 β^+ production and preclinical evaluation in tumor-bearing mice. <i>Nuclear Medicine and Biology</i> , 2014, 41, e58-e65.	0.6	60
6	Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1907-1915.	6.4	51
7	DOTA-Functionalized Polylysine: A High Number of DOTA Chelates Positively Influences the Biodistribution of Enzymatic Conjugated Anti-Tumor Antibody chCE7agf. <i>PLoS ONE</i> , 2013, 8, e60350.	2.5	28
8	L1-CAM-targeted antibody therapy and ^{177}Lu radioimmunotherapy of disseminated ovarian cancer. <i>International Journal of Cancer</i> , 2012, 130, 2715-2721.	5.1	31
9	The low-energy β^+ and electron emitter ^{161}Tb as an alternative to ^{177}Lu for targeted radionuclide therapy. <i>Nuclear Medicine and Biology</i> , 2011, 38, 917-924.	0.6	120
10	Site-Specific and Stoichiometric Modification of Antibodies by Bacterial Transglutaminase. <i>Angewandte Chemie - International Edition</i> , 2010, 49, 9995-9997.	13.8	274
11	The soluble form of the cancer-associated L1 cell adhesion molecule is a pro-angiogenic factor. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 1572-1580.	2.8	49
12	Antibodies directed against L1-CAM synergize with Genistein in inhibiting growth and survival pathways in SKOV3ip human ovarian cancer cells. <i>Cancer Letters</i> , 2008, 261, 193-204.	7.2	25
13	Modification of Different IgG1 Antibodies via Glutamine and Lysine using Bacterial and Human Tissue Transglutaminase. <i>Bioconjugate Chemistry</i> , 2008, 19, 271-278.	3.6	54
14	Copper-67 Radioimmunotherapy and Growth Inhibition by Anti-L1-Cell Adhesion Molecule Monoclonal Antibodies in a Therapy Model of Ovarian Cancer Metastasis. <i>Clinical Cancer Research</i> , 2007, 13, 603-611.	7.0	73
15	Evaluation of ^{177}Lu -DOTA-labeled aglycosylated monoclonal anti-L1-CAM antibody chCE7: influence of the number of chelators on the in vitro and in vivo properties. <i>Nuclear Medicine and Biology</i> , 2006, 33, 883-889.	0.6	39
16	Efficient Inhibition of Intra-Peritoneal Tumor Growth and Dissemination of Human Ovarian Carcinoma Cells in Nude Mice by Anti-L1-Cell Adhesion Molecule Monoclonal Antibody Treatment. <i>Cancer Research</i> , 2006, 66, 936-943.	0.9	140
17	In vivo Evaluation of ^{177}Lu - and $^{67/64}\text{Cu}$ -Labeled Recombinant Fragments of Antibody chCE7 for Radioimmunotherapy and PET Imaging of L1-CAM-Positive Tumors. <i>Clinical Cancer Research</i> , 2005, 11, 5112-5120.	7.0	79
18	Radiometal Labeling of Antibodies and Antibody Fragments for Imaging and Therapy. , 2004, 248, 481-494.		3

#	ARTICLE	IF	CITATIONS
19	Radiopharmaceuticals: From Molecular Imaging to Targeted Radionuclide Therapy. <i>Chimia</i> , 2004, 58, 731-735.	0.6	8
20	Hepatocyte Growth Factor-induced Ectodomain Shedding of Cell Adhesion Molecule L1. <i>Journal of Biological Chemistry</i> , 2004, 279, 31149-31156.	3.4	32
21	Imaging of renal carcinoma xenografts with 64 Cu-labelled anti-L1-CAM antibody chCE7. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 1066-1066.	6.4	4
22	Targeting of renal carcinoma with 67/64Cu-labeled anti-L1-CAM antibody chCE7: selection of copper ligands and PET imaging. <i>Nuclear Medicine and Biology</i> , 2003, 30, 417-427.	0.6	68
23	High-Yield Production of Recombinant Antibody Fragments in HEK-293 Cells Using Sodium Butyrate. <i>BioTechniques</i> , 2003, 34, 968-972.	1.8	37
24	Structural Determinants Required for Apical Sorting of an Intestinal Brush-border Membrane Protein. <i>Journal of Biological Chemistry</i> , 2000, 275, 6566-6572.	3.4	74
25	Analysis of presenilin 1 and presenilin 2 expression and processing by newly developed monoclonal antibodies. <i>Journal of Neuroscience Research</i> , 1999, 56, 405-419.	2.9	20
26	Zebrafish (<i>Danio rerio</i>) Presenilin Promotes Aberrant Amyloid β -Peptide Production and Requires a Critical Aspartate Residue for Its Function in Amyloidogenesis. <i>Biochemistry</i> , 1999, 38, 13602-13609.	2.5	118
27	Alzheimer's Disease Associated Presenilin-1 Holoprotein and Its 18~20 kDa C-Terminal Fragment Are Death Substrates for Proteases of the Caspase Family. <i>Biochemistry</i> , 1998, 37, 2263-2270.	2.5	69
28	Proteolytic Fragments of the Alzheimer's Disease Associated Presenilins-1 and -2 Are Phosphorylated in Vivo by Distinct Cellular Mechanisms. <i>Biochemistry</i> , 1998, 37, 5961-5967.	2.5	60
29	Truncated presenilin 2 derived from differentially spliced mRNAs does not affect the ratio of amyloid β -peptide 1-42/1-40. <i>NeuroReport</i> , 1998, 9, 3293-3299.	1.2	17
30	Caspase-mediated cleavage is not required for the activity of presenilins in amyloidogenesis and NOTCH signaling. <i>NeuroReport</i> , 1998, 9, 1481-1486.	1.2	75
31	Mutant Presenilin 2 Transgenic Mouse: Effect on an Age-Dependent Increase of Amyloid β -Protein 42 in the Brain. <i>Journal of Neurochemistry</i> , 1998, 71, 313-322.	3.9	81
32	Presenilins Are Processed by Caspase-type Proteases. <i>Journal of Biological Chemistry</i> , 1997, 272, 20655-20659.	3.4	142
33	Cellular Expression and Proteolytic Processing of Presenilin Proteins Is Developmentally Regulated During Neuronal Differentiation. <i>Journal of Neurochemistry</i> , 1997, 69, 2432-2440.	3.9	79
34	Proteolytic Processing of Human Lactase-Phlorizin Hydrolase Is a Two-Step Event: Identification of the Cleavage Sites. <i>Archives of Biochemistry and Biophysics</i> , 1996, 336, 27-34.	3.0	18
35	The Alzheimer's Disease-Associated Presenilins Are Differentially Phosphorylated Proteins Located Predominantly within the Endoplasmic Reticulum. <i>Molecular Medicine</i> , 1996, 2, 673-691.	4.4	230
36	Human Lactase-Phlorizin Hydrolase: Evidence of Dimerization in the Endoplasmic Reticulum. <i>Archives of Biochemistry and Biophysics</i> , 1995, 323, 367-372.	3.0	8

#	ARTICLE	IF	CITATIONS
37	Expression of the alpha subunit of PABA peptide hydrolase (EC 3.4.24.18) in MDCK cells. FEBS Letters, 1993, 335, 376-379.	2.8	39
38	Proteolytic processing of human intestinal lactase-phlorizin hydrolase precursor is not a prerequisite for correct sorting in Madin Darby canine kidney (MDCK) cells. FEBS Letters, 1992, 314, 224-228.	2.8	16